127-Member Organization to Cut 99 Employees

Arsenal Biosciences announced on August 31, 2026, that it will restructure its business around in vivo CAR-T and lay off 99 employees across all departments. This represents approximately 78% of the 127 employees remaining after a 50% restructuring in September 2025, marking a de facto restart with only core personnel. The sharp reduction two years after raising $325 million in Series C funding in March 2024 indicates that the development costs and clinical risks of its ex vivo solid tumor platform exceeded capital efficiency limits.

Clinical Assets to Be Considered for Out-Licensing

The company's lead candidate, AB-2100, is an ex vivo integrated circuit T-cell therapy that induces CAR expression via PSMA signaling to target CA9. Its Phase 1/2 trial NCT06245915 for recurrent clear cell renal cell carcinoma will continue without additional enrollment. AB-1015 is an ex vivo CAR-T that sequentially recognizes ALPG·ALPP and mesothelin (MSLN), while inhibiting FAS·PTPN2. Its Phase 1 trial NCT05617755 for platinum-resistant ovarian cancer has also completed enrollment. The company plans to present these clinical data at future conferences and explore strategic alternatives such as asset sales or licensing for its existing technologies and assets. Prostate cancer candidate AB-3028 is at the investigational new drug application stage, and AB-7000 is in preclinical development, but both will be reassessed for development priority alongside the new in vivo platform.

In Vivo Manufacturing Strategy to Transform Cost Structure

In vivo CAR-T bypasses patient T-cell collection, centralized manufacturing, quality control, and reinfusion by directly reprogramming T-cells in the body using targeted viral vectors or lipid nanoparticles (LNPs). If successful, it could reduce administration wait times and manufacturing facility burdens, expanding CAR-T accessibility beyond hematological cancers to autoimmune diseases and broader tumor types. However, non-target cell transduction, in vivo distribution, genomic integration risks from persistent vectors, and immune responses to repeated dosing remain key safety variables to resolve in clinical trials.

Phase 1 Competition Already Underway

In vivo CAR-T has no FDA, EMA, or PMDA-approved products yet, and even the most advanced candidates are in Phase 1. Eli Lilly (LLY)'s BCMA-targeting KLN-1010, AstraZeneca (AZN)'s BCMA-targeting ESO-T01, and Gilead Sciences (GILD)-affiliated Kite's CD20-targeting INT2104 have all entered clinical trials. Novartis (NVS)'s Kymriah (tisagenlecleucel), the first FDA-approved CAR-T in August 2017 for CD19-targeting ex vivo therapy, has established the manufacturing model that in vivo approaches aim to replace. The global CAR-T therapeutics market is projected to grow from $5.8 billion in 2025 to $22.3 billion by 2033, presenting significant opportunity, but Arsenal Bio remains a late entrant needing to demonstrate new clinical candidates and vector design.